Imino-2H-Chromene Based Derivatives as Potential Anti-Alzheimer's Agents: Design, Synthesis, Biological Evaluation and in Silico Study. 2022

Mahshid Attarroshan, and Omidreza Firuzi, and Aida Iraji, and Shahrzad Sharifi, and Marjan Tavakkoli, and Mahmmod Vesal, and Mahsima Khoshneviszadeh, and Somayeh Pirhadi, and Najmeh Edraki
Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

A new series of imino-2H-chromene derivatives were rationally designed and synthesized as novel multifunctional agents against Alzheimer's disease. A set of phenylimino-2H-chromenes as well as the newly synthesized iminochromene derivatives were evaluated as BACE1, acetylcholinesterase (AChE), and butyrylcholinesterase (BuChE) inhibitors. The results indicated that among the iminochromene set, 10c bearing fluorobenzyl moiety was the most potent BACE1 inhibitor with an IC50 value 6.31 μM. In vitro anti-cholinergic activities demonstrated that compound 10a bearing benzyl pendant was the best inhibitor of AChE (% inhibition at 30 μM=24.4) and BuChE (IC50 =3.3 μM). Kinetic analysis of compound 10a against BuChE was also performed and showed a mixed-type inhibition pattern. The neuroprotective assessment revealed that compound 11b, a phenylimino-2H-chromene derivative with hydroxyethyl moiety, provided 32.3 % protection at 25 μM against Aβ-induced PC12 neuronal cell damage. In addition, docking and simulation studies of the most potent compounds against BACE1 and BuChE confirmed the experimental results.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D002091 Butyrylcholinesterase An aspect of cholinesterase (EC 3.1.1.8). Pseudocholinesterase,Benzoylcholinesterase,Butyrylthiocholinesterase
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D000110 Acetylcholinesterase An enzyme that catalyzes the hydrolysis of ACETYLCHOLINE to CHOLINE and acetate. In the CNS, this enzyme plays a role in the function of peripheral neuromuscular junctions. EC 3.1.1.7. Acetylcholine Hydrolase,Acetylthiocholinesterase,Hydrolase, Acetylcholine
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001578 Benzopyrans Compounds with a core of fused benzo-pyran rings. Benzopyran,Chromene,Chromenes
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining

Related Publications

Mahshid Attarroshan, and Omidreza Firuzi, and Aida Iraji, and Shahrzad Sharifi, and Marjan Tavakkoli, and Mahmmod Vesal, and Mahsima Khoshneviszadeh, and Somayeh Pirhadi, and Najmeh Edraki
July 2023, Natural product research,
Mahshid Attarroshan, and Omidreza Firuzi, and Aida Iraji, and Shahrzad Sharifi, and Marjan Tavakkoli, and Mahmmod Vesal, and Mahsima Khoshneviszadeh, and Somayeh Pirhadi, and Najmeh Edraki
December 2020, Journal of enzyme inhibition and medicinal chemistry,
Mahshid Attarroshan, and Omidreza Firuzi, and Aida Iraji, and Shahrzad Sharifi, and Marjan Tavakkoli, and Mahmmod Vesal, and Mahsima Khoshneviszadeh, and Somayeh Pirhadi, and Najmeh Edraki
December 2021, Journal of enzyme inhibition and medicinal chemistry,
Mahshid Attarroshan, and Omidreza Firuzi, and Aida Iraji, and Shahrzad Sharifi, and Marjan Tavakkoli, and Mahmmod Vesal, and Mahsima Khoshneviszadeh, and Somayeh Pirhadi, and Najmeh Edraki
May 2018, European journal of medicinal chemistry,
Mahshid Attarroshan, and Omidreza Firuzi, and Aida Iraji, and Shahrzad Sharifi, and Marjan Tavakkoli, and Mahmmod Vesal, and Mahsima Khoshneviszadeh, and Somayeh Pirhadi, and Najmeh Edraki
January 2018, Current computer-aided drug design,
Mahshid Attarroshan, and Omidreza Firuzi, and Aida Iraji, and Shahrzad Sharifi, and Marjan Tavakkoli, and Mahmmod Vesal, and Mahsima Khoshneviszadeh, and Somayeh Pirhadi, and Najmeh Edraki
August 2018, Molecules (Basel, Switzerland),
Mahshid Attarroshan, and Omidreza Firuzi, and Aida Iraji, and Shahrzad Sharifi, and Marjan Tavakkoli, and Mahmmod Vesal, and Mahsima Khoshneviszadeh, and Somayeh Pirhadi, and Najmeh Edraki
March 2019, Journal of medicinal chemistry,
Mahshid Attarroshan, and Omidreza Firuzi, and Aida Iraji, and Shahrzad Sharifi, and Marjan Tavakkoli, and Mahmmod Vesal, and Mahsima Khoshneviszadeh, and Somayeh Pirhadi, and Najmeh Edraki
August 2012, Journal of enzyme inhibition and medicinal chemistry,
Mahshid Attarroshan, and Omidreza Firuzi, and Aida Iraji, and Shahrzad Sharifi, and Marjan Tavakkoli, and Mahmmod Vesal, and Mahsima Khoshneviszadeh, and Somayeh Pirhadi, and Najmeh Edraki
October 2022, International journal of molecular sciences,
Mahshid Attarroshan, and Omidreza Firuzi, and Aida Iraji, and Shahrzad Sharifi, and Marjan Tavakkoli, and Mahmmod Vesal, and Mahsima Khoshneviszadeh, and Somayeh Pirhadi, and Najmeh Edraki
April 2015, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!